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Introduction
Semaphorin 3A (sema3A) plays a regulatory role in
immune responses, mainly affecting the activation of reg-
ulatory T cells. It has been found to correlate with dis-
ease activity in rheumatoid arthritis and systemic lupus
erythematosus. Familial Mediterrenean Fevere (FMF) is
an autoinflammatory disease; yet a possible role for regu-
latory T cells has been described.
Aim
To evaluate the expression of sema3A in peripheral blood,
on B cells and on regulatory T cells, of FMF patients dur-
ing attack, in remission and with smoldering disease, in
comparison with healthy controls.
Methods
17 FMF patients in attack and in remission, 8 FMF
patients with smoldering disease and 12 healthy controls
were enrolled. Smoldering disease was defined in FMF
patients with high CRP level (above 20mg/dL) without
concurrent symptoms of serositis, arthritis nor concomi-
tant known infectious disease. Sema3A in peripheral blood
was measured by ELISA and expression of sema3A on
regulatory T cells and regulatory B cells was evaluated by
FACS analysis. FMF patients were evaluated for demo-
graphics and disease severity by the Mor severity score.
Results
The 3 groups of patients: a. FMF in attack and remission,
b. FMF with smoldering disease and c. healthy controls
were similar with regard to age (38.1±10.2 vs.48±15
vs.43.1±3.4) and female gender (8 [47%] vs. 4 [50%] vs.5
[41%]). The age of onset was 10 years ±7.9 in group a and
15 years ±6.3 in group b. The mean colchicine dose was
similar between groups a and b (1.9±0.48 vs. 2.25±0.5) and
so was the Mor severity score (3.2± 1.9 and 2.8± 1.6).
Semaphorin 3A expression on regulatory T cells in FMF
patients during an attack was lower than in remission and
in healthy controls (57.2%± 8.3 vs. 77.2%±10.3 vs. 88.7%±
3.6%, p<0.01) but similar to patients with smoldering
disease.
Semaphorin 3A expression on regulatory B cells were
lower in FMF patients during an attack than FMF in
remission and in healthy controls (72.9%±8.5 vs. 83.4%
±5.8 vs. 82.6%±6.4 ng/ml, p<0.05), but was similar to
patients with smoldering disease.
Semaphorin 3A concentration in peripheral blood as
evaluated by ELISA was lower in FMF patients during an
attack, in smoldering disease and in remission than in
healthy controls (242.3±9.8 ng/ml vs. 258.9±11.5 ng/ml
vs. 232.5±22.7 ng/ml vs. 323.3±160.2 ng/ml, p<0.05).
Conclusion
Sema3A expression on regulatory T cells and regulatory B
cells is low in FMF patients during an attack and in smol-
dering disease compared to the expression in FMF remis-
sion and in healthy controls. Regulatory T cells have been
described to increase one week after an attack and were
speculated to have a role in the termination of FMF
attacks. A decrease in sema3A in an attack and normaliza-
tion at remission may help explain the decrease and subse-
quent normalization of regulatory T cells. The role of
regulatory T cells and semaphorin 3A in termination of
FMF attacks needs further evaluation on a wider scale.
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